Sep 06, 2023 Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Jul 31, 2023 Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
Jul 27, 2023 Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
Jun 28, 2023 Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
May 23, 2023 Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 15, 2023 Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Mar 31, 2023 Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar 30, 2023 Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Mar 02, 2023 Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma